Detalhe da pesquisa
1.
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Gut
; 72(1): 129-140, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197323
2.
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.
Cell Mol Life Sci
; 79(4): 204, 2022 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332383
3.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 23(1): 77-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914889
4.
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
J Hepatol
; 75(3): 600-609, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051329
5.
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
J Hepatol
; 73(6): 1460-1469, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32710922
6.
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Am J Hematol
; 95(5): 510-520, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32052473
7.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet
; 389(10088): 2492-2502, 2017 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28434648
8.
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
J Immunother Cancer
; 12(3)2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38458639
9.
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Nat Med
; 30(1): 218-228, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903504
10.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
J Clin Oncol
; 41(9): 1747-1757, 2023 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512738
11.
Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents.
Clin Cancer Res
; 28(20): 4509-4520, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998012
12.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
JAMA Oncol
; 6(11): e204564, 2020 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001135
13.
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Clin Cancer Res
; 23(8): 1929-1936, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27756788